Stanford Dodges Major IP Blow, But Professors Face Setback in Roche Trade Secrets Battle

Filed in the U.S. District Court in California, the lawsuit claimed that the professors and Foresight Diagnostics illegally used Roche’s trade secrets to develop technology related to liquid biopsy—a cutting-edge method for detecting cancer through blood samples. Roche argued that their internal research and patent documents were unfairly leveraged by the Stanford-affiliated team, resulting in a breach of trust and intellectual theft.

While the university itself managed to partially extricate itself from the lawsuit, the court allowed the claims against the professors and Foresight Diagnostics to move forward. U.S. District Judge Edward Davila ruled that there was sufficient evidence suggesting the professors may have had access to confidential Roche data and subsequently used it in their academic work and business ventures.

Stanford, as an institution, succeeded in dismissing several key claims due to sovereign immunity and lack of direct evidence linking the university administration to the alleged misuse of trade secrets. The court agreed that Stanford's involvement, from an organizational standpoint, did not meet the threshold for direct liability.

However, the ruling was less favorable for the individual professors. The court emphasized the need to assess whether they violated non-disclosure agreements or overstepped the bounds of academic-industry collaboration. Foresight Diagnostics, co-founded by the professors, remains central to the investigation as it has commercialized technology remarkably similar to Roche’s earlier research.

Roche’s lawsuit also sheds light on the challenges multinational corporations face in safeguarding their intellectual assets, especially when collaborating with top-tier universities. On the flip side, researchers argue that broad claims over trade secrets can sometimes stifle academic freedom and slow down the translation of research into real-world medical solutions.